We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

CVS Hits Pfizer With Antitrust Suit Over Lipitor Delay

Law360 (August 3, 2018, 10:22 PM EDT) -- CVS Pharmacy Inc. launched an antitrust suit in New Jersey federal court Friday accusing Pfizer Inc. of fraudulently obtaining a patent and conspiring with Ranbaxy Laboratories Ltd. to delay generic competition to the cholesterol drug Lipitor, saying the alleged scheme cost the pharmacy giant hundreds of millions of dollars.

CVS paid “artificially inflated prices” for its atorvastatin calcium needs because the two drugmakers entered into an agreement in which Ranbaxy agreed to not sell its generic version of Pfizer’s Lipitor in the U.S. until Nov. 30,...
To view the full article, register now.